Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population worldwide. Obesity is a major risk factor for development and progression of NAFLD and weight loss is an effective intervention for the management of NAFLD....

Descripción completa

Detalles Bibliográficos
Autores principales: Tsankof, Alexandra, Neokosmidis, Georgios, Koureta, Evgenia, Veneti, Stavroula, Cholongitas, Evangelos, Tziomalos, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478023/
https://www.ncbi.nlm.nih.gov/pubmed/36120448
http://dx.doi.org/10.3389/fendo.2022.984041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478023/
https://www.ncbi.nlm.nih.gov/pubmed/36120448
http://dx.doi.org/10.3389/fendo.2022.984041

Ejemplares similares